Tetra Bio-Pharma Inc (TSXV: TBP) has released an update regarding its clinical study for the veterinary treatment of eye pain found in animals suffering from indolent corneal ulcers.
In 2019, the company received approval from Health Canada to organize a cannabinoid drug manufacturing facility in New Brunswick where it can develop ophthalmic drugs which have the potential to treat eye pain in animals. Since then, the facility has been validated, and Tetra’s researchers have developed the sterile PPP003 drug. The company plans to begin the associated clinical trial regarding the effectiveness of the ophthalmic drug on companion animals in early 2020.
Depending on the results of the clinical trial, this new study has the potential to facilitate further research and additional clinical trials using the cannabinoid drug to treat human subjects suffering from eye diseases.
Tetra Bio-Pharma is a Canadian biopharmaceutical company focused on developing cannabinoid treatments and prescription drugs through its approved clinical program.
Tetra Bio-Pharma Inc is currently trading at $0.50 on the TSXV.
Information for this briefing was found via Sedar and Tetra Bio-Pharma Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
Market Movers: Tetra Bio-Pharma
Cannabis adjacent pharma-co Tetra Bio-Pharma (TSXV: TBP) was the most active symbol on the TSX.V...